Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer.
FDG-PET/CT
clinical impact
metastatic breast cancer
response monitoring
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Aug 2021
13 Aug 2021
Historique:
received:
04
08
2021
accepted:
11
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
We compared response categories and impacts on treatment decisions for metastatic breast cancer (MBC) patients that are response-monitored with contrast-enhanced computed-tomography (CE-CT) or fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT). A comparative diagnostic study was performed on MBC patients undergoing response monitoring by CE-CT (
Identifiants
pubmed: 34439232
pii: cancers13164080
doi: 10.3390/cancers13164080
pmc: PMC8392540
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Acta Oncol. 2016;55(1):59-67
pubmed: 25833330
Breast. 2017 Dec;36:89-95
pubmed: 28988610
J Natl Cancer Inst Monogr. 2015 May;2015(51):21-3
pubmed: 26063880
Radiology. 2020 Dec;297(3):622-629
pubmed: 33078998
Support Care Cancer. 2019 Oct;27(10):3793-3798
pubmed: 30721369
Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1666-1673
pubmed: 25971426
Diagnostics (Basel). 2021 Apr 19;11(4):
pubmed: 33921580
Oncol Lett. 2018 Oct;16(4):4151-4158
pubmed: 30214554
Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):450-60
pubmed: 22183107
Eur J Cancer. 2016 Jul;62:132-7
pubmed: 27189322
J Cancer. 2014 Jan 05;5(1):58-68
pubmed: 24396498
Acad Radiol. 2014 Sep;21(9):1177-84
pubmed: 24998693
Cancers (Basel). 2019 Aug 15;11(8):
pubmed: 31443324
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Diagnostics (Basel). 2020 Nov 24;10(12):
pubmed: 33255442
J Mol Diagn. 2020 Feb;22(2):247-261
pubmed: 31837432
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Lancet Oncol. 2020 Apr;21(4):519-530
pubmed: 32171426
Eur J Gynaecol Oncol. 2015;36(6):672-6
pubmed: 26775349
Oncol Lett. 2020 Oct;20(4):87
pubmed: 32863920
Cancer Imaging. 2014 Apr 22;14:13
pubmed: 25608599
J Nucl Med. 2016 Feb;57 Suppl 1:34S-9S
pubmed: 26834099
AJR Am J Roentgenol. 2019 Aug;213(2):254-265
pubmed: 31063423
Clin Transl Imaging. 2021 Apr 27;:1-11
pubmed: 33937141
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1428-1437
pubmed: 28462446
J Clin Med. 2019 Sep 02;8(9):
pubmed: 31480647
Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1906-14
pubmed: 17713766
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
Ann Oncol. 2018 Aug 1;29(8):1634-1657
pubmed: 30032243
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Mol Imaging Biol. 2019 Feb;21(1):1-10
pubmed: 29516387
Lancet. 2017 Mar 18;389(10074):1134-1150
pubmed: 27865536
Radiology. 2016 Aug;280(2):576-84
pubmed: 26909647
Diagnostics (Basel). 2019 Aug 27;9(3):
pubmed: 31461923
J Clin Oncol. 2016 Jun 1;34(16):1889-97
pubmed: 27001573
Eur Radiol. 2011 Dec;21(12):2604-17
pubmed: 21887484
Breast Cancer Res. 2019 Oct 17;21(1):113
pubmed: 31623649
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
J Nucl Med. 2015 Nov;56(11):1674-80
pubmed: 26294295